Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Theravance Biopharma stock

Learn how to easily invest in Theravance Biopharma stock.

Theravance Biopharma Inc is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 359 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Theravance Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TBPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Theravance Biopharma stock price (NASDAQ: TBPH)

Use our graph to track the performance of TBPH stocks over time.

Theravance Biopharma shares at a glance

Information last updated 2022-01-24.
Latest market close$8.75
52-week range$6.10 - $22.74
50-day moving average $9.69
200-day moving average $12.51
Wall St. target price$10.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.38

Buy Theravance Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Theravance Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theravance Biopharma price performance over time

Historical closes compared with the close of $8.75 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-23) -18.83%
3 months (2021-10-26) 11.46%
6 months (2021-07-26) -35.99%
1 year (2021-01-26) -52.75%
2 years (2020-01-24) -66.59%
3 years (2019-01-25) 27.61
5 years (2017-01-26) 28.9

Theravance Biopharma financials

Revenue TTM $59.1 million
Gross profit TTM $-189,096,000
Return on assets TTM -37.74%
Return on equity TTM 0%
Profit margin 0%
Book value $-2.42
Market capitalisation $613.9 million

TTM: trailing 12 months

Theravance Biopharma share dividends

We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.

Theravance Biopharma share price volatility

Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $6.1 up to $22.74. A popular way to gauge a stock's volatility is its "beta".

TBPH.US volatility(beta: 0.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.8454. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).

Theravance Biopharma overview

Theravance Biopharma, Inc. , a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc.

Frequently asked questions

What percentage of Theravance Biopharma is owned by insiders or institutions?
Currently 17.843% of Theravance Biopharma shares are held by insiders and 84.6% by institutions.
How many people work for Theravance Biopharma?
Latest data suggests 359 work at Theravance Biopharma.
When does the fiscal year end for Theravance Biopharma?
Theravance Biopharma's fiscal year ends in December.
Where is Theravance Biopharma based?
Theravance Biopharma's address is: Ugland House, George Town, Cayman Islands, KY1-1104
What is Theravance Biopharma's ISIN number?
Theravance Biopharma's international securities identification number is: KYG8807B1068
What is Theravance Biopharma's CUSIP number?
Theravance Biopharma's Committee on Uniform Securities Identification Procedures number is: G8807B106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site